Hyqvia Infusion
Immunoglobulin G (IgG)
5g/50ml
BAXALTA INNOVATIONS GmbH
| Pack size | 1 glass vial human normal immunoglobulin (50 ml) + 1 vial recombinant human hyaluronidase (excipient -2.5 ml) |
|---|---|
| Dispensing mode | POM |
| Source | AUSTRIA |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 1773.50 AED |
Indications
Hyqvia Infusion is used for:
IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barrũ syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott/Aldrich syndrome and inflammatory skin diseases.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Immunoglobulin G (IgG) :
Mechanism of Action
IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage �ctaggingA or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab')2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.
Note
Hyqvia 5g/50ml Infusion manufactured by BAXALTA INNOVATIONS GmbH. Its generic name is Immunoglobulin G (IgG). Hyqvia is availble in United Arab Emirates.
Farmaco UAE drug index information on Hyqvia Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.